Indoco Remedies Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/k67lexdbqi11egiw3i7vtxg0.pdf

Key Takeaways


India Business: Growth Above Market, Weather a Transient Headwind

Aditi Panandikar: "This year because the rains have come early and they refuse to go away. I mean probably this is the longest monsoon we've had in the last decade. So it is doing a bit of a flip flop for some of our acute products."

USFDA & U.S. Business: A Tentative Turning Point

Aditi Panandikar: "And just this morning, we have got a receipt from U.S. FDA saying that they acknowledge that we are ready. So which is the first positive communication we have got from their side that they acknowledge that we are ready."
Aditi Panandikar: "So what we are doing at this stage is we are trying to derisk from our side by getting our larger products approved and approved in other facilities outside of our own from other CMOs. We feel that is a better strategy at this stage than us further investing on U.S."

Europe & Regulated Markets: Inflection Expected from Q3


Subsidiaries: Investment Phase Nearing an End

Aditi Panandikar: "We were talking of EBITDA breaking even earlier and improvement in drain. But yes, I mean, you're asking me questions, so I tell you the numbers. And I'm trying to be safe because I've been told I should not put my foot in the mouth."

Costs, Cash Flow & Balance Sheet


Strategic Outlook: Revenue Target Reset, Margin Promise Intact

Aditi Panandikar: "2027, which was our immediate agenda, looks a little bit distant at this stage. I feel that we will have to take a delay of probably 18 months to realize that beyond 2027. That is only for the top line, though. The margin improvement, you will see substantial."

Guidance & Commitments

CommitmentSpecificsTimeline
USFDA sterile plant auditFDA acknowledged readiness; audit scheduling awaitedNo date; if by Dec, revenue impact in Q4
U.S. sterile revenue uplift₹30 cr incremental quarterly if clean auditPost-audit, Q4 if audit by December
Europe revenue rampUpside expected now that largest buyer approvals receivedFrom Q3 FY26 onwards
Europe annual revenue₹300 crNext year (FY27), "100% if not more"
Debt repayment₹52 cr in H2 FY26; ~₹140 cr annually thereafterH2 FY26 and ongoing
Maintenance capex₹50-70 cr annually; <₹150 cr totalNext 3 years
R&D spend reductionBring down to 4% of sales"In the very first year as sales pick up"
FPP subsidiary break-evenBreak even"In a couple of quarters"
Warren Remedies OTC break-evenEBITDA break-even (OTC side faster than API)"Another 2 quarters" of bleeding, then improvement
3-year revenue target~₹3,500 cr (from ₹1,500 cr base)3 years
₹5,000 cr revenue targetDelayed by ~18 months beyond 2027Beyond 2027
India business growthHigher single-digit growthQuarters to come
Clarity Pharma revenue updateRevenue updateBy March
FPP licensed-in U.S. products approvalAt least 2 years from logging with USFDA~2027-2028

Key Metrics

MetricQ2 FY26
Consolidated net revenue₹471.8 cr, +9.6% YoY and +9.5% QoQ
Stand-alone net revenue₹429.3 cr, +8.8% YoY and +11.3% QoQ
Consolidated EBITDA margin9.1% at ₹43.1 cr, vs 9.3% at ₹40.3 cr YoY and 4.1% at ₹17.5 cr QoQ
Stand-alone EBITDA margin12.4% at ₹53.4 cr, vs 13.4% at ₹52.9 cr YoY and 3.8% at ₹14.8 cr QoQ
Domestic formulation revenue₹226.1 cr, vs ₹234.6 cr same quarter last year
International formulation revenue₹153.3 cr, vs ₹126.2 cr same quarter last year
Regulated markets revenue₹91.5 cr, vs ₹86.6 cr same quarter last year
U.S. business revenue₹33.6 cr, vs ₹24.7 cr same quarter last year
Europe revenue₹54.7 cr, vs ₹59.9 cr same quarter last year
South Africa, Australia and New Zealand revenue₹3.3 cr, vs ₹2 cr same quarter last year
U.S. and Canada sales₹334 cr, improvement over ₹28 cr in the prior comparable period
R&D spend as a percentage of sales~5%, with a target to reduce to 4% in the very first year as sales pick up
Combined loss of FPP Holding and Warren Remedies subsidiaries₹23 cr for the quarter
Warren Remedies OTC revenue₹29 cr of the subsidiary's ₹34 cr quarterly revenue
Debt repayment commitment for H2 FY26~₹52 cr
Maintenance capex guidance₹50–70 cr per year going forward
3-year consolidated revenue target~₹3,500 cr, from a base of ~₹1,500 cr in FY25